Delving into the Latest Updates on Imeik Technology Development Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Skin and Musculoskeletal Diseases

Cardiovascular Diseases

Small molecule drug

Enzyme

Toxin

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	2

Top 5 Drug Type	Count

Toxin	1
Small molecule drug	1
Enzyme	1

Top 5 Target	Count

Hyaluronic acid	1
SCNA(Sodium voltage-gated channel alpha subunits)	1
SNAP25(Synaptosomal-associated protein 25)	1

以原研药 PLIAGLIS ®为阳性对照，通过随机、双盲、自身对照的临床试验，验证试验药物利多卡因丁卡因乳膏用于成人浅层皮肤手术前对完整皮肤局部麻醉的有效性。通过实验室检查、临床症状、体征、不良事件等，验证利多卡因丁卡因乳膏的安全性。

[Translation]

Using the original drug PLIAGLIS ® as a positive control, a randomized, double-blind, self-controlled clinical trial was conducted to verify the effectiveness of the experimental drug lidocaine tetracaine cream for local anesthesia of intact skin before superficial skin surgery in adults. The safety of lidocaine tetracaine cream was verified through laboratory tests, clinical symptoms, signs, adverse events, etc.

Start Date29 Mar 2023

Sponsor / Collaborator

Shandong Liangfu Pharmaceutical Co., Ltd

[+1]

CTR20211394 / CompletedPhase 3

多中心、双盲、随机、平行、阳性对照的Ⅲ期试验，评价注射用A型肉毒毒素HUTOX相较于BOTOX®在中度至重度眉间纹受试者中的有效性和安全性

[Translation] A multicenter, double-blind, randomized, parallel, active-controlled Phase III trial to evaluate the efficacy and safety of HUTOX for injection compared with BOTOX® in subjects with moderate to severe glabellar lines

主要目的：评价在中国的中至重度眉间纹成年受试者中，使用试验药品 Huons BioPharma Co., Ltd.生产的注射用A型肉毒毒素（HUTOX）在注射后4周的最大皱眉时眉间纹改善率是否非劣于对照药品BOTOX ®

[Translation]

Primary objective: To evaluate whether the investigational product, botulinum toxin type A for injection (HUTOX), manufactured by Huons BioPharma Co., Ltd., is non-inferior to the control product BOTOX® in terms of improvement in glabellar lines at maximal frown 4 weeks after injection in Chinese adult subjects with moderate to severe glabellar lines.

Start Date03 Dec 2021

Sponsor / Collaborator

Imeik Technology Development Co., Ltd.

[+1]

100 Clinical Results associated with Imeik Technology Development Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Imeik Technology Development Co., Ltd.

Login to view more data

7

Literatures (Medical) associated with Imeik Technology Development Co., Ltd.

01 Apr 2024·Aesthetic Plastic Surgery

Infraorbital Rejuvenation Combined with Thread-Lifting and Non-cross-linked Hyaluronic Acid Injection: A Retrospective, Case-Series Study

Article

Author: Yang, Wei ; Liao, Zhi-Feng ; Wang, Shi-Wei ; Liu, Fang-Cen ; Luo, Sheng-Kang ; Li, Xin

AbstractBackgroundInfraorbital aging develops during the natural aging process. Various treatment options offer unique benefits, accompanied by diverse side effect profiles, and can be synergistically combined to optimize results. This study aimed to evaluate the efficacy of a comprehensive approach involving non-cross-linked hyaluronic acid injection and smooth absorbable PPDO (poly p-dioxanone) thread insertion for infraorbital rejuvenation.MethodsThis retrospective case series study enrolled ten female patients with infraorbital aging from March 2022 to April 2023. Clinical outcomes, patient satisfaction, and adverse events were assessed at 1, 3, and 6 months posttreatment.ResultsThe median Global Aesthetic Improvement Scale scores evaluated by the operator and blinded evaluator were 1.70 ± 0.42 and 1.80 ± 0.35, respectively, at six months posttreatment. The median Allergan Infraorbital Hollows Scale determined by the operator was 1.15 ± 0.34 at six months posttreatment, whereas the scores evaluated by the blinded evaluator were 1.15 ± 0.53. At six months after treatment, 50% of patients were satisfied, and an additional 40% reported strong satisfaction with the clinical improvement following treatment. No serious adverse events, such as infections, lumps, irregularities, Tyndall effect, hematoma, or skin necrosis, occurred during the treatment period.ConclusionsThe combination of PPDO thread insertion and non-cross-linked hyaluronic acid injection yielded satisfactory and effective clinical outcomes with no occurrence of serious adverse events for infraorbital rejuvenation. We anticipate that this study will contribute to the advancement of novel treatment options for infraorbital aging.Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.

01 Feb 2024·Journal of Cosmetic Dermatology

Experimental investigation of biostimulatory effects after polydioxanone thread insertion in a pig model

Article

Author: Wang, Shiwei ; He, Tong ; Wang, Jieqing ; Su, Diya

AbstractBackgroundPolydioxanone (PDO) threads have been widely used to tighten and lift the facial soft tissue.ObjectiveThis research aims to determine the collagenation and inflammation changes that occur in the adipose tissue over time when different types of threads are implanted.Methods & MaterialsThree threads types, PDO, poly glycolic‐co‐lactic acid (PGLA), and nylon, were inserted in the subcutaneous fat of 12‐month‐old Bama miniature pigs. Collagen production and inflammatory response were evaluated by hematoxylin and eosin and Masson trichrome staining at 1, 4, 12, 24, and 48 weeks.ResultsThe integrity of the PDO thread lasted up to 24 weeks with mild inflammation and collagen production. The PGLA thread integrity lasted until 12 weeks and had a strong inflammatory response. The nylon thread's integrity was maintained for 48 weeks and showed minor inflammation and collagen production.ConclusionOur data suggest that PDO thread is the best choice for clinicians, as it has a mild action process with minimal irritation, moderate collagen production, a reasonable explanation time, with obvious bridging fibrous tissue, and thickening action for the superficial fascia.

01 Dec 2023·Journal of Cosmetic Dermatology

Histopathologic analysis of hyaluronic acid composite solution following intravascular injection: Variability and safety

Article

Author: Zhang, Youliang ; Wang, Shiwei ; Luo, Shengkang ; Niu, Huanyun ; Yu, Hao ; Chen, Yin

AbstractBackgroundAlthough a composite solution of non‐crosslinked hyaluronic acid is generally considered safe, few studies have investigated its safety after intravascular injection.MethodsMale Sprague–Dawley rats were administered 0.05 mL of a non‐crosslinked hyaluronic acid composite solution via intravascular injection into bilateral inferior epigastric arteries (IEA). Artery samples were obtained at multiple time points for histopathologic analysis. Bilateral abdominal flaps supplied by the IEA were lifted and the same dose of solution was injected into the artery, and flap survival was analyzed.ResultsHistopathologic analysis showed that the non‐crosslinked hyaluronic acid composite solution remained temporarily in the artery lumen following intravascular injection. With continuous blood flow, the filler gradually disintegrated and the artery became recanalized. At 24 h, no filler remained in the lumen. At 7 days after the filler was injected into the IEA feeding the flap, there was no significant difference between the experimental and control groups with respect to flap survival rate.ConclusionsNon‐crosslinked hyaluronic acid composite solution is relatively safe when a minimal volume is administered by intravascular injection. The filler will remain in the vessel for a short time, after which the vessel recanalizes.

100 Deals associated with Imeik Technology Development Co., Ltd.

Login to view more data

100 Translational Medicine associated with Imeik Technology Development Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

1

IND Approval

Phase 3 Clinical

1

NDA/BLA

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Botulinum toxin type A(Aquavit Pharmaceuticals/Huons) ( SNAP25 )	Glabellar frown lines More	NDA/BLA
Lidocaine/Tetracaine ( SCNA )	Anesthesia More	Phase 3
Semaglutide biosimilar(QL Biopharma) ( GLP-1R )	Obesity More	IND Approval
Recombinant Human Hyaluronidase (Beijing Novotel) ( Hyaluronic acid )	-	IND Application
Liraglutide biosimilar(Nobot Biotechnology) ( GLP-1R )	Obesity More	Pending